undamentalytics Newsletter
Sign in

Abcellera Biologics Inc. cash flow statement

In fiscal 2025, Abcellera Biologics Inc.'s operations generated −$131m of cash; it spent $42.8m on capital projects, leaving free cash flow of −$174m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations323245277−44−109−131−95
Depreciation and amortisation25142824131821
Stock-based pay18314964685651
Capital spending410587177784325
Free cash flow−113186207−121−187−174−120
Free cash flow after stock pay−25155157−185−255−230−171
Shares issued—523——————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABCL vs CYTKABCL vs CUVLABCL vs RXRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abcellera Biologics Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abcellera Biologics Inc.